Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Coronary artery endothelial dysfunction: Basic concepts

Frank W Sellke, MD
Amir Lerman, MD
R Jay Widmer, MD, PhD
Filippo Crea, MD
Section Editor
Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA
Deputy Editor
Gordon M Saperia, MD, FACC


The coronary arterial circulation, which consists of conductance and resistance vessels, plays a major role in the delivery of blood to the myocardium. The endothelium is the layer of cells that lines these blood vessels. This layer maintains blood vessel (vascular) tone, regulates hemostasis, acts as barrier to potentially toxic materials, and regulates inflammation. Notably, the metabolic regulation of coronary blood flow that takes place at the site of resistance vessels allows a perfect matching between oxygen supply and demand. The increase of blood flow in the presence of an increase of oxygen demand is mainly mediated by the release of tiny amounts of free oxygen radicals.

Endothelial dysfunction is the inability of the endothelium to optimally perform one or more of these functions. Dysfunction of the endothelium is the principal determinant of chronic microvascular dysfunction but also may occur in the larger conduit arteries, especially when atherosclerosis is present. The principal clinical consequence of microcirculatory dysfunction is myocardial ischemia but can also include vascular thrombosis, increased vascular permeability, and diastolic changes in the myocardium. Endothelial dysfunction plays a key role in determining myocardial ischemia in all clinical manifestations of ischemic heart disease. Furthermore, the decrement in the noninvasive measurement of peripheral endothelial function has been shown in a large systematic review and meta-analysis encompassing over 17,000 patients to double the cardiovascular risk in moderate-risk individuals [1].

This topic will focus on basic concepts of normal endothelial function and dysfunction. More clinical aspects are discussed separately. (See "Coronary artery endothelial dysfunction: Clinical aspects".)


The endothelium is one of the largest organs in the body and it interacts with nearly every other organ or organ system [2,3]. It is a single (mono) layer of cells serving multiple purposes:

Maintenance of hemostasis, the balance between thrombosis and clotting

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: May 16, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Matsuzawa Y, Kwon TG, Lennon RJ, et al. Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2015; 4.
  2. Wolinsky H. A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. Circ Res 1980; 47:301.
  3. Augustin HG, Kozian DH, Johnson RC. Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes. Bioessays 1994; 16:901.
  4. Janssens SP, Shimouchi A, Quertermous T, et al. Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J Biol Chem 1992; 267:14519.
  5. Förstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23:1121.
  6. Reis SE, Holubkov R, Lee JS, et al. Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women's Ischemia Syndrome Evaluation (WISE) study. J Am Coll Cardiol 1999; 33:1469.
  7. Moroi M, Zhang L, Yasuda T, et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998; 101:1225.
  8. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A 1995; 92:1137.
  9. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14:753.
  10. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ Res 1996; 79:748.
  11. Arnal JF, Yamin J, Dockery S, Harrison DG. Regulation of endothelial nitric oxide synthase mRNA, protein, and activity during cell growth. Am J Physiol 1994; 267:C1381.
  12. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997; 3:158.
  13. Sellke FW, Wang SY, Stamler A, et al. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol 1996; 271:H713.
  14. Li J, Brown LF, Hibberd MG, et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996; 270:H1803.
  15. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994; 94:2036.
  16. Wu HM, Yuan Y, McCarthy M, Granger HJ. Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism. Am J Physiol 1996; 271:H1087.
  17. Morbidelli L, Chang CH, Douglas JG, et al. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996; 270:H411.
  18. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99:2625.
  19. Pipili-Synetos E, Papageorgiou A, Sakkoula E, et al. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 1995; 116:1829.
  20. Pipili-Synetos E, Sakkoula E, Haralabopoulos G, et al. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 1994; 111:894.
  21. Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002; 124:28.
  22. Ruel M, Wu GF, Khan TA, et al. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation 2003; 108 Suppl 1:II335.
  23. Voisine P, Bianchi C, Ruel M, et al. Inhibition of the cardiac angiogenic response to exogenous vascular endothelial growth factor. Surgery 2004; 136:407.
  24. Sodha NR, Clements RT, Boodhwani M, et al. Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol 2009; 296:H428.
  25. Boodhwani M, Nakai Y, Mieno S, et al. Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. Ann Thorac Surg 2006; 81:634.
  26. Voisine P, Bianchi C, Khan TA, et al. Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction. J Thorac Cardiovasc Surg 2005; 129:1414.
  27. Ruel M, Song J, Sellke FW. Protein-, gene-, and cell-based therapeutic angiogenesis for the treatment of myocardial ischemia. Mol Cell Biochem 2004; 264:119.
  28. Suuronen EJ, Hazra S, Zhang P, et al. Impairment of human cell-based vasculogenesis in rats by hypercholesterolemia-induced endothelial dysfunction and rescue with L-arginine supplementation. J Thorac Cardiovasc Surg 2010; 139:209.
  29. Robich MP, Chu LM, Oyamada S, et al. Myocardial therapeutic angiogenesis: a review of the state of development and future obstacles. Expert Rev Cardiovasc Ther 2011; 9:1469.
  30. Lassaletta AD, Chu LM, Sellke FW. Therapeutic neovascularization for coronary disease: current state and future prospects. Basic Res Cardiol 2011; 106:897.
  31. Boodhwani M, Mieno S, Feng J, et al. Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine. J Thorac Cardiovasc Surg 2008; 135:117.
  32. Saitoh S, Kiyooka T, Rocic P, et al. Redox-dependent coronary metabolic dilation. Am J Physiol Heart Circ Physiol 2007; 293:H3720.
  33. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003; 41:1387.
  34. Miura H, Wachtel RE, Loberiza FR Jr, et al. Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels. Circ Res 2003; 92:151.
  35. Li H, Gutterman DD, Rusch NJ, et al. Nitration and functional loss of voltage-gated K+ channels in rat coronary microvessels exposed to high glucose. Diabetes 2004; 53:2436.
  36. Vergnani L, Hatrik S, Ricci F, et al. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : key role of L-arginine availability. Circulation 2000; 101:1261.
  37. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106:3073.
  38. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002; 106:1211.
  39. Li L, Chen W, Rezvan A, et al. Tetrahydrobiopterin deficiency and nitric oxide synthase uncoupling contribute to atherosclerosis induced by disturbed flow. Arterioscler Thromb Vasc Biol 2011; 31:1547.
  40. Tiefenbacher CP, Bleeke T, Vahl C, et al. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 2000; 102:2172.
  41. Alexander LM, Kutz JL, Kenney WL. Tetrahydrobiopterin increases NO-dependent vasodilation in hypercholesterolemic human skin through eNOS-coupling mechanisms. Am J Physiol Regul Integr Comp Physiol 2013; 304:R164.
  42. Hein TW, Zhang C, Wang W, et al. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 2003; 17:2328.
  43. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152:493.e1.
  44. Böger RH, Lentz SR, Bode-Böger SM, et al. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001; 100:161.
  45. Elesber AA, Solomon H, Lennon RJ, et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J 2006; 27:824.
  46. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56:e50.
  47. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358:2127.
  48. Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001; 104:1114.
  49. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003; 23:1185.
  50. Boos CJ, Goon PK, Lip GY. Circulating endothelial progenitor cells. N Engl J Med 2005; 353:2613.
  51. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348:593.
  52. Murasawa S, Kawamoto A, Horii M, et al. Niche-dependent translineage commitment of endothelial progenitor cells, not cell fusion in general, into myocardial lineage cells. Arterioscler Thromb Vasc Biol 2005; 25:1388.
  53. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89:E1.
  54. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353:999.
  55. Gössl M, Mödder UI, Gulati R, et al. Coronary endothelial dysfunction in humans is associated with coronary retention of osteogenic endothelial progenitor cells. Eur Heart J 2010; 31:2909.
  56. Curtis AM, Edelberg J, Jonas R, et al. Endothelial microparticles: sophisticated vesicles modulating vascular function. Vasc Med 2013; 18:204.
  57. Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990; 81:1586.
  58. Ishida T, Kawashima S, Hirata Ki, et al. Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries. Circulation 2001; 103:1289.
  59. Chilian WM, Dellsperger KC, Layne SM, et al. Effects of atherosclerosis on the coronary microcirculation. Am J Physiol 1990; 258:H529.
  60. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338:1546.
  61. Yokoyama I, Momomura S, Ohtake T, et al. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Circulation 1999; 100:117.
  62. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87:86.
  63. Marcus M. The Coronary Circulation in Health and Disease, 1, McGraw-Hill, New York 1983.
  64. Marcus ML, Harrison DG, Chilian WM, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987; 75:I19.
  65. Rajappan K, Rimoldi OE, Dutka DP, et al. Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation 2002; 105:470.
  66. Brooks BA, Franjic B, Ban CR, et al. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab 2008; 10:739.
  67. Rajappan K, Rimoldi OE, Camici PG, et al. Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation 2003; 107:3170.
  68. Kaye DM, Ahlers BA, Autelitano DJ, Chin-Dusting JP. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 2000; 102:2707.
  69. Widmer RJ, Lerman LO, Lerman A. Low-flow motion in the vascular ocean. Circ Cardiovasc Interv 2012; 5:617.
  70. Liuba P, Karnani P, Pesonen E, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation 2000; 102:1039.
  71. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102:994.
  72. Blum A, Tamir S, Mualem K, et al. Endothelial dysfunction is reversible in Helicobacter pylori-positive subjects. Am J Med 2011; 124:1171.
  73. Joensen JB, Juul S, Henneberg E, et al. Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. Atherosclerosis 2008; 196:937.
  74. Zahn R, Schneider S, Frilling B, et al. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 2003; 107:1253.
  75. Beckman JA, Thakore A, Kalinowski BH, et al. Radiation therapy impairs endothelium-dependent vasodilation in humans. J Am Coll Cardiol 2001; 37:761.
  76. Chow AY, Chin C, Dahl G, Rosenthal DN. Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol 2006; 24:925.
  77. Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). Circulation 2004; 109:568.
  78. Cannon RO 3rd, Epstein SE. "Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 1988; 61:1338.
  79. Park KW, Dai HB, Lowenstein E, et al. Isoflurane and halothane attenuate endothelium-dependent vasodilation in rat coronary microvessels. Anesth Analg 1997; 84:278.
  80. Park KW, Dai HB, Lowenstein E, Sellke FW. Flow-induced dilation of rat coronary microvessels is attenuated by isoflurane but enhanced by halothane. Anesthesiology 1998; 89:132.
  81. Park KW, Dai HB, Lowenstein E, Sellke FW. Effect of sevoflurane and desflurane on the myogenic constriction and flow-induced dilation in rat coronary arterioles. Anesthesiology 1999; 90:1422.
  82. Piana RN, Wang SY, Friedman M, Sellke FW. Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion. Circulation 1996; 93:544.
  83. Quillen JE, Sellke FW, Brooks LA, Harrison DG. Ischemia-reperfusion impairs endothelium-dependent relaxation of coronary microvessels but does not affect large arteries. Circulation 1990; 82:586.
  84. Sellke FW, Shafique T, Schoen FJ, Weintraub RM. Impaired endothelium-dependent coronary microvascular relaxation after cold potassium cardioplegia and reperfusion. J Thorac Cardiovasc Surg 1993; 105:52.
  85. Ruel M, Khan TA, Voisine P, et al. Vasomotor dysfunction after cardiac surgery. Eur J Cardiothorac Surg 2004; 26:1002.
  86. Métais C, Li J, Simons M, Sellke FW. Serotonin-induced coronary contraction increases after blood cardioplegia-reperfusion: role of COX-2 expression. Circulation 1999; 100:II328.
  87. Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999; 99:2113.
  88. Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84:1589.
  89. Katz SD, Krum H, Khan T, Knecht M. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 1996; 28:585.
  90. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 97:363.
  91. Patel AR, Kuvin JT, Pandian NG, et al. Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation. J Am Coll Cardiol 2001; 37:195.
  92. Vallbracht KB, Schwimmbeck PL, Kühl U, et al. Differential aspects of endothelial function of the coronary microcirculation considering myocardial virus persistence, endothelial activation, and myocardial leukocyte infiltrates. Circulation 2005; 111:1784.
  93. Davis SF, Yeung AC, Meredith IT, et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 1996; 93:457.
  94. Hiemann NE, Wellnhofer E, Knosalla C, et al. Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation 2007; 116:1274.
  95. Dedkov EI, Perloff JK, Tomanek RJ, et al. The coronary microcirculation in cyanotic congenital heart disease. Circulation 2006; 114:196.
  96. Frank MW, Harris KR, Ahlin KA, Klocke FJ. Endothelium-derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary collateral vessels. J Am Coll Cardiol 1996; 27:658.
  97. Laham RJ, Rezaee M, Li J, et al. Adaptive responses of ischemic microvessels: Increased expression of inducible nitric oxide synthase but not endothelial nitric oxide synthase (abstract). Circulation 1997; 96:I355.
  98. Ravichandran LV, Johns RA, Rengasamy A. Direct and reversible inhibition of endothelial nitric oxide synthase by nitric oxide. Am J Physiol 1995; 268:H2216.
  99. Uematsu M, Ohara Y, Navas JP, et al. Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. Am J Physiol 1995; 269:C1371.
  100. Li J, Partovian C, Li J, et al. Modulation of microvascular signaling by heparan sulfate matrix: studies in syndecan-4 transgenic mice. Microvasc Res 2002; 64:38.
  101. Zhang Y, Li J, Partovian C, et al. Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. Am J Physiol Heart Circ Physiol 2003; 284:H2078.
  102. Harada K, Friedman M, Lopez JJ, et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996; 270:H1791.
  103. Sellke FW, Wang SY, Friedman M, et al. Basic FGF enhances endothelium-dependent relaxation of the collateral-perfused coronary microcirculation. Am J Physiol 1994; 267:H1303.
  104. Bauters C, Asahara T, Zheng LP, et al. Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. Circulation 1995; 91:2802.
  105. Martin EA, Prasad A, Rihal CS, et al. Endothelial function and vascular response to mental stress are impaired in patients with apical ballooning syndrome. J Am Coll Cardiol 2010; 56:1840.
  106. Sara JD, Zhang M, Gharib H, et al. Hypothyroidism Is Associated With Coronary Endothelial Dysfunction in Women. J Am Heart Assoc 2015; 4:e002225.
  107. Hasin T, Matsuzawa Y, Guddeti RR, et al. Attenuation in peripheral endothelial function after continuous flow left ventricular assist device therapy is associated with cardiovascular adverse events. Circ J 2015; 79:770.
  108. Feng J, Cohn WE, Parnis SM, et al. New continuous-flow total artificial heart and vascular permeability. J Surg Res 2015; 199:296.
  109. Prasad M, Reriani M, Khosla S, et al. Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women. Vasc Health Risk Manag 2014; 10:533.